Clinical trials
Observational Glomerulonephritis, IGA trials in China
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
18 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2011 | 1 |
| 2012 | 2 |
| 2016 | 2 |
| 2019 | 1 |
| 2020 | 3 |
| 2021 | 2 |
| 2022 | 3 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Recruiting | 8 |
| Completed | 6 |
| Unknown status | 3 |
| Active, not recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Guangdong Provincial People's Hospital | 3 |
| Ruijin Hospital | 2 |
| Sun Yat-sen University | 2 |
| Chinese PLA General Hospital | 1 |
| George (Beijing) Clinical Research Co. Ltd. | 1 |
| Peking University First Hospital | 1 |
| Shenzhen Second People's Hospital | 1 |
| Sichuan Provincial People's Hospital | 1 |
| Tang-Du Hospital | 1 |
| The Fourth Affiliated Hospital of Zhejiang University School of Medicine | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Glomerulonephritis, IGA | 18 |
| Glomerulonephritis, Membranous | 3 |
| Diabetic Nephropathies | 2 |
| Glomerulonephritis | 2 |
| Glomerulosclerosis, Focal Segmental | 2 |
| Kidney Diseases | 2 |
| Renal Insufficiency, Chronic | 2 |
| Disease | 1 |
| Kidney Failure, Chronic | 1 |
| Nephrosis, Lipoid | 1 |
Trials
Showing 1 to 18 of 18. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.